Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Rademikibart - Suzhou Connect Biopharmaceuticals/Simcere Pharmaceutical Group

Next Previous
Drug Profile

Rademikibart - Suzhou Connect Biopharmaceuticals/Simcere Pharmaceutical Group

Alternative Names: CBP 201; Ledechibaimab - Suzhou Connect Biopharmaceuticals/Simcere Pharmaceutical Group; Leruiping - Suzhou Connect Biopharmaceuticals/Simcere Pharmaceutical Group; SIM-0718

Latest Information Update: 11 Sep 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Suzhou Connect Biopharmaceuticals
  • Developer Simcere Pharmaceutical Group; Suzhou Connect Biopharmaceuticals
  • Class Anti-inflammatories; Antiallergics; Antiasthmatics; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action Interleukin 4 receptor alpha subunit antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Atopic dermatitis
  • Phase III Asthma
  • Phase II Chronic obstructive pulmonary disease; Rhinosinusitis
  • Phase I Respiratory tract disorders

Most Recent Events

  • 21 Aug 2026 Phase-II clinical trials in Asthma (Treatment-experienced) in USA (IV) (NCT07705737)
  • 21 Aug 2026 Phase-II clinical trials in Chronic obstructive pulmonary disease (Treatment-experienced) in USA (IV) (NCT07705737)
  • 13 Aug 2026 Suzhou Connect Biopharmaceuticals completes enrolment in the phase-II Seabreeze STAT COPD trial in Chronic obstructive pulmonary disease in the US, Argentina, Australia, Georgia, Serbia and the UK (NCT06940154)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top